ALKS Alkermes plc

33.58
+0.42  (+1%)
Previous Close 33.16
Open 33.38
Price To Book 4.5
Market Cap 5268111764
Shares 156,882,423
Volume 1,034,004
Short Ratio
Av. Daily Volume 983,010

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA approval announced July 2, 2018.
Aripiprazole Lauroxil NanoCrystal Dispersion (ALNCD)
Schizophrenia
Phase 3 data due early 2020.
ALKS 3831 - ENLIGHTEN-Early
Schizophrenia - young adults
Phase 3 data released November 29, 2018 met co-primary endpoints. NDA filing due mid-2019.
ALKS 3831 - ENLIGHTEN-2
Schizophrenia
CRL received March 15, 2010.
BYDUREON
Type 2 diabetes
Approved October 5 2015. sNDA filed for 2-month option with approval announced June 6, 2017.
Aristada
Schizophrenia
NDA filing announced December 17, 2018. NDA acceptance announced February 25, 2019. PDUFA estimate December 24, 2019.
Diroximel fumarate (BIIB098)
Multiple sclerosis (MS)
Phase 3 trial did not meet endpoint - February 2017. Second trial is ongoing.
ALKS 6428
Opioid dependence
CRL announced February 1, 2019.
ALKS 5461
Major depressive disorder
Phase 3 preliminary data released June 30, 2017. Primary endpoint met - adverse events included weight gain.
ALKS 3831 - ENLIGHTEN-1
Schizophrenia
Phase 1 initial data at SITC November 9, 2018.
ALKS 4230
Solid tumors
Phase 3 data released April 9, 2019 - primary endpoint met.
Aristada and Invega Sustenna
Schizophrenia
Phase 1 initiation announced February 26, 2019.
ALKS 4230 + Keytruda - ARTISTRY-2
Solid tumors

Latest News

  1. Alkermes to Host Conference Call to Discuss First Quarter 2019 Financial Results
  2. Earnings Preview: Alkermes (ALKS) Q1 Earnings Expected to Decline
  3. The Daily Biotech Pulse: NASH Cheer For Intercept, Gilead Layoffs, BioDelivery Licenses Constipation Drug
  4. Alkermes Reports Positive Data From Schizophrenia Study
  5. See what the IHS Markit Score report has to say about Alkermes Plc.
  6. Alkermes says long-acting drugs could help schizophrenics stay on medication longer
  7. Alkermes Announces Positive Topline Results From Innovative Study of ARISTADA® and INVEGA SUSTENNA® for the Treatment of Schizophrenia
  8. Alkermes Announces Departure of Jim Robinson
  9. The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
  10. Alkermes Expands Awards Program With Focus on Advancing Research in Schizophrenia
  11. Drug companies that benefit from the war on opioid addiction
  12. Alkermes to Present New ALKS 3831 Data From ENLIGHTEN-2 and Interim Extension Safety Study Results at 2019 Congress of the Schizophrenia International Research Society
  13. Recro Pharma Falls as FDA Denies Approval to Pain Candidate
  14. Top Insider Buys Highlight
  15. Alkermes Focuses on Pipeline, Depends on Partners for Funds
  16. Industry Consortium Launched to Qualify Biomarkers for Schizophrenia Drug Development
  17. Why Is Alkermes (ALKS) Up 4.7% Since Last Earnings Report?
  18. Alkermes plc’s (NASDAQ:ALKS) Path To Profitability